About Us
- About Us
Products
- Products
  - Products
  - Our Product Pricing
R&D
- R&D
Sustainability
- Sustainability
Investor Relations
Contact Us
News & Media
Join Us
- Join Us

Newsroom

In This Section

Leadership Team
Specialty Generics
Core Strengths
Our Story
Partnering
Patient Stories
158th Anniversary

News Release

Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at Kidney Week 2024

Print Page | RSS Feeds | Email Alerts

Contact Media Relations
Investor Relations

Building On Our Heritage

More than 150 years of quality, integrity and service.

Learn More

Join Us

Invest in your own career with Mallinckrodt and let’s do something dynamic together..

Learn How

Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company.© 2025 Mallinckrodt. Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc,(in examination under Part 10 of the Companies Act 2014), which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland.

UnitedHealthcare creates and publishes the Machine-Readable Files on behalf of Mallinckrodt. To link to the Machine-Readable Files, please click on the URL provided: transparency-in-coverage.uhc.com.

Other Links:

Safety Data Sheets
Calif. Supply Chain Disclosure
Patents
UK Modern Slavery Act Disclosure
Canadian Modern Slavery Act Report
Ireland Gender Pay Gap Report
UHC Transparency in Coverage
C-TPAT Statement of Support
Vulnerability Disclosure Policy

Contact Us Terms of Use Cookie Policy Privacy Policy Privacy Choices CCPA Icon